Vetmulin 125 mg/ml Oral Solution for use in drinking water for pigs

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

şimdi satın al

Ürün özellikleri Ürün özellikleri (SPC)
12-06-2017

Aktif bileşen:

Tiamulin hydrogen fumarate

Mevcut itibaren:

Huvepharma NV

ATC kodu:

QJ01XQ01

INN (International Adı):

Tiamulin hydrogen fumarate

Doz:

125 milligram(s)/millilitre

Farmasötik formu:

Oral solution

Reçete türü:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapötik grubu:

Pigs

Terapötik alanı:

tiamulin

Terapötik endikasyonlar:

Antibacterial

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2010-02-05

Ürün özellikleri

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmulin 125 mg/ml Oral
Solution for use in drinking water for pigs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE
Tiamulin hydrogen fumarate
125 mg (equivalent to 101.2 mg tiamulin)
EXCIPIENTS
Methyl parahydroxybenzoate (E218)
0.90 mg
Propyl parahydroxybenzoate
0.10 mg
For the full list of excipients: see section 6.1
3 PHARMACEUTICAL FORM
Oral solution for use in drinking water.
Clear colourless to slightly yellow liquid.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In pigs
For the treatment of swine dysentery caused by or further complicated
by tiamulin-susceptible_ Brachyspira_
_hyodysenteriae._
For the treatment of enzootic pneumonia and the reduction of lesions
caused by tiamulin-susceptible_ Mycoplasma_
_hyopneumoniae._
The presence of the disease in the herd should be established before
use.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
substance or to any of the excipient.
Do not use in the case of resistance to tiamulin.
Do not administer products containing monensin, salinomycin, narasin,
maduramicin or other ionophores during or for
at least seven days before or after treatment with the product. See
also section 5.1. and 4.8.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_3_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_5_
_5_
_3_
_9_
_p_
_a_
_g_

                                
                                Belgenin tamamını okuyun